Celldex Therapeutics, based in Boston, MA, is a leading biopharmaceutical company specializing in the development of transformative antibody therapeutics at the intersection of mast cell biology. Their lead program, barzolvolimab, is a humanized monoclonal antibody inhibitor of KIT, targeting a core pathological driver of severe inflammatory, allergic, and autoimmune diseases to potentially offer a best-in-class treatment option for patients.
Driven by deep expertise in antibody-based immunotherapies, Celldex's proprietary antibody programs and technologies are backed by robust in-house capabilities, facilitating the optimized discovery and development of innovative scientific programs. With a focus on improving patient lives, Celldex is dedicated to advancing research and clinical studies to address unmet medical needs in various therapeutic areas.
Generated from the website